Login
03-05-2023 : 769 Pharmacists work as Medical Representative, of which 39 work as Senior Medical Representative * 02-06-2020 : 216 non Pharmacists work as Medical Representative, and 54 work as Senior Medical Representative * 05-06-2023 : In Lebanon, 88 generic medicinal products are more expensive than their Originators * 31-12-2019 : A medicinal product refused in Europe is marketed in Lebanon * 05-06-2023 : At least 332 medicinal products are available on the Lebanese market and are not available in the country of origin * 05-06-2023 : The price of the most expensive medicine available in Lebanon is 30434557 LL * 05-06-2023 : At least 1309 medicinal products are more expensive in Lebanon than in the countries of origin * 01-01-2019 : Daktavira, a generic of Daklinza, is registered in Lebanon but has no public price * 31-12-2019 : 352 medicinal products have been declared as non-marketed or withdrawn * 09-11-2021 : 64.72% of lebanese pharmacists are female * 31-12-2019 : 486 medicines were submitted to the Ministry of Health for a marketing authorization, and 514 medicines were registered to date * 15-06-2018 : The Minister of Public Health, has decided to suspend the commercialization of AB Slim (Ab Care Medical Herbs), which contains sibutramine, sildenafil and phenolphthalein * 01-06-2020 : Some Non-Marketed medicines are still imported * 01-06-2020 : Ixempra, a medicinal product withdrawn in Europe is imported to lebanon * 01-06-2020 : A vaccine made in India, removed from WHO list of prequalified vaccines, is submitted for registration in Lebanon * 01-06-2020 : Lebanon has 14 CROs, and is ranked as one of the largest countries in the world in clinical studies. According to the WHO, 817 clinical studies are currently conducted in Lebanon. * 05-01-2021 : * 01-10-2023 : Adakveo is now withdrawn from use in the European Union due to lack of therapeutic efficacy *
- General Info
- Route
- ATC
- Indications
- Composition
- Excipients
- Side Effects
- Alternative Treatments
- Available In
-
May be acceptable
May be acceptable
| Nivaquine* : | |
| Type | Medicine Non Marketed |
| Originator | B |
| Agent | Mersaco |
| Distributor | Mersaco |
| Laboratory | Sanofi |
| Responsible Party | Sanofi Aventis France |
| Origin | France |
| Manufacturer | Famar Lyon |
| Origin | France |
| ATC | P01BA01 |
Nivaquine* :
Nivaquine* :
Nivaquine* :
Nivaquine* :
Nivaquine* :
| Hazard Level |
|---|
| ◼ Major |
| ◼ Moderate |
| ◼ Minor |
| ◼ Safe |
Nivaquine* :
| Frequency | Percentage |
|---|---|
| Very Common | ≥ 1/10 |
| Common | ≥ 1/100 - < 1/10 |
| Uncommon | ≥ 1/1,000 - < 1/100 |
| Rare | ≥ 1/10,000 - < 1/1,000 |
| Very Rare | < 1/10,000 |
| Unknown | Cannot be Estimated |
| Effect | Frequency |
|---|---|
| Accommodation disorder | Common |
| Aggressiveness | Rare |
| Agitation | Rare |
| Agranulocytosis | Very rare |
| Alopecia | Rare |
| Anaphylactic reactions | Common |
| Anaphylactoid reactions | Common |
| Angioedema (Angioneurotic oedema) (Quincke oedema) | Common |
| Anxiety | Rare |
| Arrhythmia | Not known |
| Cardiac failure | Very rare |
| Cardiomyopathy | Very rare |
| Cephalea | Very Common |
| Confusion | Rare |
| Convulsion | Very rare |
| Corneal opacity | Rare |
| Deafness | Very rare |
| Depression | Common |
| Dermatitis exfoliative | Not known |
| DRESS (Drug reaction with eosinophilia and systemic symptoms) | Not known |
| Dyskinesia | Not known |
| Dystonia | Not known |
| Eosinophilic pneumonia | Very rare |
| Erythema multiforme | Not known |
| Extrapyramidal disorder | Not known |
| Gastrointestinal discomfort | Very Common |
| Hallucination | Rare |
| Hepatic enzyme increased | Very rare |
| Hepatitis | Very rare |
| Hypoacusis | Very rare |
| Hypoglycaemia | Not known |
| Insomnia | Very Common |
| Lightheadedness | Common |
| Lyell Syndrome (Toxic epidermal necrolysis) | Very rare |
| Macular degeneration | Not known |
| Maculopathy | Not known |
| Mucosal pigmentation | Rare |
| Myopathy | Rare |
| Nail pigmentation | Rare |
| Nausea | Very Common |
| Neuropathy | Rare |
| Neutropenia | Very rare |
| Photosensitivity | Very rare |
| Pigmentation disorder | Rare |
| Polyneuritis | Rare |
| Protrusion tongue | Not known |
| Pruritus | Very Common |
| Psoriasis exacerbation | Rare |
| Psychotic episode | Very rare |
| QT interval prolonged (QT prolongation) | Not known |
| Retinopathy | Not known |
| Skin Eruption | Common |
| Sleep disorder (Sleep disturbance) | Rare |
| Stevens-Johnson syndrome | Very rare |
| Suicidal behaviour | Not known |
| Thrombocytopenia (Thrombopenia) | Very rare |
| Tinnitus | Very rare |
| Torsade de pointes | Not known |
| Torticollis | Not known |
| Ventricular fibrillation | Not known |
| Ventricular tachycardia | Not known |
| Vision blurred | Common |
| Vomiting | Very Common |
Nivaquine* :
| NB : Products With Same Indication |
Different Units By MoH Code
Nivaquine* MoH 1760 :
| Form | Tablet |
| Packaging | Blisters (Al/PVC) |
| Package Size | Box of 20 |
| Strength | 100mg |
| NSSF | ✘ |
| Quarantine | ✘ |
| Reg. Number | 1838/72 |
| Submission date | 01/01/1972 |
| Registration Year | 1972 |
| Archived Date | 01/03/2022 |
Price Comparison
| ● Country: | France | |
| ● Package Size: | 20 | |
| ● Public Price: | 3.16 EUR | ( 306,128.16 LBP ) |
| ● Pack size unit used: | 20 | |
| ● Cost/Unit: | 0,158 EUR | ( 0.00 LBP ) |
| ● Reference: | ansm | |
| ● Pricing Date: | 15/05/2021 | |
| ● Type: | Medicine Authorised |
| ● Country: | Tunisia | |
| ● Package Size: | Boîte de 20 | |
| ● Public Price: | 7.5 TND | ( 216,487.50 LBP ) |
| ● Pack size unit used: | 20 | |
| ● Cost/Unit: | 0,375 TND | ( 0.00 LBP ) |
| ● Pricing Date: | 04/02/2019 | |
| ● Type: | Medicine Authorised |
- ◼ Lebanon
- ◼ Country of Origin
- ◼ Reference Countries
- ◼ Other Countries
You have to register to view this info
Upload File
Drop File
Uploading, Please wait ....
